Skip to main content

Table 2 BAL/serum cytokine concentrations in RSV infected mice treated with motavizumab compared with untreated RSV infected controls on day 5 after inoculation. Each group consisted of 4 samples randomly selected from two independent experiments.

From: Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model

  BAL (D5)   SERUM (D5)  
  RSV Untreated RSV Motavizumab p value RSV Untreated RSV Motavizumab p value
IFN-γ 1291.29 ± (561.3) 640.84 ± (388.8) 0.02 116.58 ± (43.1) 28.29 ± * (35.7) 0.02
MCP-1 291.10 ± (128.6) 132.0 ± (105.8) 0.15 311.95 ± (78.3) 343.26 ± (81.2) 0.6
RANTES 118.82 ± (28.3) 48.50 ± (51.9) 0.055 ND ND ---
IL-10 59.7 ± (52.91) 25.68 ± (18.5) 0.3 15.18 (10.0–71.9) 23.28 (15.18–48.82) 0.6
TNF-α 13.65 (10.32–17.35) 10.0 (10.0–11.18) 0.2 ND ND ---
IL-12p70 ND ND --- 39.72 ± (20.6) 38.07 ± (5.8) 0.7
IL-8 (KC) 209.9 ± (88.8) 117.75 ± (54.2) 0.12 32.54 ± (27.96) 25.82 ± (19.6) 0.7
IL-6 101.38 ± (51.22) 30.46 ± (28.87) 0.052 ND ND ND
IL-1β 34.63 ± (34.59) 52.25 ± (54.3) 0.6 180.66 ± (87.03) 126.09 ± (58.3) 0.4
IL-1α 12.59 ± (3.05) 13.84 ± (3.7) 0.6 ND ND ND
IL-17 ND ND --- 13.02 (10.0–22.98) 10.61 (10.0–11.77) 0.5
  1. Note: Data are shown as mean ± SD, or medians and 25–75% range as appropriate according to whether they were normally distributed. ND (non-detected).